Topic analysis

Iran war squeezes India's pharma supply chain

The Iran war is exerting significant pressure on India's $50 billion pharmaceutical industry—a leading global supplier of generic drugs, accounting for 20% of global volumes and 47% of U.S. generic prescriptions—through rising energy and freight costs, surging raw material prices (including 60-70% of active pharmaceutical ingredients sourced from China), and supply chain disruptions that threaten higher drug prices and potential shortages. Industry experts warn that while current inventory buffers are mitigating immediate impacts, prolonged conflicts could lead to production shutdowns and global supply issues, with India's government implementing short-term relief measures and urging increased domestic API production to reduce import reliance.